designer491 Acleyrin ( NASDAQ: SLRN ) said that izobikep, its candidate for hidradenitis suppurativa, met its primary endpoint in a phase 3 study. At 12 weeks, 33% of patients receiving izokibep 160mg weekly achieved the endpoint, HiSCR75, compared to 21% on placebo. The company continued dosing patients through 16 weeks, and based on data from two-thirds of patients at that time point, responses have deepened over time.
Acelyrin is also investigating izobikep in an ongoing phase 2b/3 trial in uveitis, with top-line data expected Q4. The company also said that it plans to begin a phase 3 study of lonigutamab for thyroid eye disease in Q1 2025. In addition, Acleyrin will lay off one-third of its workforce.
As a result, its cash runway will be extended to mid-2027. The stock is up ~4% in after-hours trading. More on Acelyrin Seeking Alpha’s Quant Rating on Acelyrin Historical earnings data for Acelyrin Financial information for Acelyrin.
